Molecular imaging can accelerate anti-angiogenic drug development and testing
- 28 August 2007
- journal article
- Published by Springer Science and Business Media LLC in Nature Clinical Practice Oncology
- Vol. 4 (10), 556-557
- https://doi.org/10.1038/ncponc0929
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probesNature Medicine, 2007
- Early in vivo assessment of angiostatic therapy efficacy by molecular MRIThe FASEB Journal, 2007
- How molecular imaging is speeding up antiangiogenic drug developmentMolecular Cancer Therapeutics, 2006
- Positron Emission Tomography Using [18F]Galacto-RGD Identifies the Level of Integrin αvβ3 Expression in ManClinical Cancer Research, 2006
- Molecular Imaging in the Development of Cancer TherapeuticsAnnual Review of Medicine, 2006
- Noninvasive Visualization of the Activated αvβ3 Integrin in Cancer Patients by Positron Emission Tomography and [18F]Galacto-RGDPLoS Medicine, 2005
- Micro-PET Imaging of αvβ3-Integrin Expression with 18F-Labeled Dimeric RGD PeptideMolecular Imaging, 2004
- Imaging gastrointestinal tumours using vascular endothelial growth factor-165 (VEGF165) receptor scintigraphyAnnals Of Oncology, 2003
- Molecular imaging of cancer with positron emission tomographyNature Reviews Cancer, 2002
- Requirement of Vascular Integrin α v β 3 for AngiogenesisScience, 1994